Tissue-specific deregulation of selected HDACs characterizes ALS progression in mouse models: Pharmacological characterization of SIRT1 and SIRT2 pathways

Cell Death and Disease

Volumn 5, Issue 6, 2014, Pages

  Valle, C ^a,b   Salvatori, I ^b,c   Gerbino, V ^b,c   Rossi, S ^b,c   Palamiuc, L ^d,e   Rene F ^d,e   Carri M T ^b,c  

^a CNR   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d Laboratoire des Mecanismes Centraux et Peripheriques de la Neurodegenerescence   (France)

^e UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE; HISTONE DEACETYLASE 11; HISTONE DEACETYLASE 5; MESSENGER RNA; PROTEIN P53; SIRTUIN 1; SIRTUIN 2; TUBULIN; UNCLASSIFIED DRUG; COPPER ZINC SUPEROXIDE DISMUTASE; ENZYME INHIBITOR; SIRT1 PROTEIN, MOUSE; SIRT2 PROTEIN, MOUSE; SUPEROXIDE DISMUTASE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DAMAGE; CELL PROTECTION; CONTROLLED STUDY; DISEASE COURSE; GENE MUTATION; HISTONE ACETYLATION; MODULATION; MOUSE; MUSCLE; MYOBLAST; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SPINAL CORD; SURVIVAL; AMINO ACID SUBSTITUTION; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; MISSENSE MUTATION; PATHOLOGY; TRANSGENIC MOUSE;

AMINO ACID SUBSTITUTION; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; MICE; MICE, TRANSGENIC; MUTATION, MISSENSE; SIRTUIN 1; SIRTUIN 2; SUPEROXIDE DISMUTASE;

EID: 84903792981     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.247     Document Type: Article

References (40)

1. Cozzolino M, Pesaresi MG, Gerbino V, Grosskreutz J, Carrì MT. Amyotrophic lateral sclerosis: new insights into underlying molecular mechanisms and opportunities for therapeutic intervention. Antioxid Redox Signal 2012; 17: 1277-1330.
2. Schmalbach S, Petri S. Histone deacetylation and motor neuron degeneration. CNS Neurol Disord Drug Targets 2010; 9: 279-284.
3. Saha RN, Pahan K. HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis. Cell Death Differ 2006; 13: 539-550.
4. Rouaux C, Jokic N, Mbebi C, Boutillier S, Loeffler JP, Boutillier AL. Critical loss of CBP/p300 histone acetylase activity by caspase-6 during neurodegeneration. EMBO J 2003; 22: 6537-6549.
5. Rouaux C, Panteleeva I, RenéF, Gonzalez de Aguilar JL, Echaniz-Laguna A, Dupuis L et al. Sodium valproate exerts neuroprotective effects in vivo through CREB-binding proteindependent mechanisms but does not improve survival in an amyotrophic lateral sclerosis mouse model. J Neurosci 2007; 27: 5535-5545.
6. Rouaux C, Loeffler JP, Boutillier AL. Targeting CREB-binding protein (CBP) loss of function as a therapeutic strategy in neurological disorders. Biochem Pharmacol 2004; 68: 1157-1164.
7. Ryu H, Smith K, Camelo SI, Carreras I, Lee J, Iglesias AH et al. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem 2005; 93: 1087-1098.
8. Sugai F, Yamamoto Y, Miyaguchi K, Zhou Z, Sumi H, Hamasaki T et al. Benefit of valproic acid in suppressing disease progression of ALS model mice. Eur J Neurosci 2004; 20: 3179-3183.
9. Del Signore SJ, Amante DJ, Kim J, Stack EC, Goodrich S, Cormier K et al. Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis mice. Amyotroph Lateral Scler 2009; 10: 85-94.
10. Yoo YE, Ko CP. Treatment with trichostatin A initiated after disease onset delays disease progression and increases survival in a mouse model of amyotrophic lateral sclerosis. Exp Neurol 2011; 231: 147-159.
11. Garbes L, Riessland M, Wirth B. Histone acetylation as a potential therapeutic target in motor neuron degenerative diseases. Curr Pharm Des 2013; 19: 5093-5104.
12. Janssen C, Schmalbach S, Boeselt S, Sarlette A, Dengler R, Petri S. Differential histone deacetylase mRNA expression patterns in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 2010; 69: 573-581.
13. Williams AH, Valdez G, Moresi V, Qi X, McAnally J, Elliott JL et al. MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice. Science 2009; 326: 1549-1554.
14. Bruneteau G, Simonet T, BauchéS, Mandjee N, Malfatti E, Girard E et al. Muscle histone deacetylase 4 upregulation in amyotrophic lateral sclerosis: potential role in reinnervation ability and disease progression. Brain 2013; 136(Pt 8): 2359-2368.
15. d'Ydewalle C, Bogaert E, Van Den Bosch L. HDAC6 at the intersection of neuroprotection and neurodegeneration. Traffic 2012; 13: 771-779.
16. Fiesel FC, Schurr C, Weber SS, Kahle PJ. TDP-43 knockdown impairs neurite outgrowth dependent on its target histone deacetylase. Mol Neurodegener 2011; 6: 76.
17. Taes I, Timmers M, Hersmus N, Bento-Abreu A, Van Den Bosch L, Van Damme P et al. Hdac6 deletion delays disease progression in the SOD1G93A mouse model of ALS. Hum Mol Genet 2013; 22: 1783-1790.
18. Gal J, Chen J, Barnett KR, Yang L, Brumley E, Zhu H. HDAC6 regulates mutant SOD1 aggregation through two SMIR motifs and tubulin acetylation. J Biol Chem 2013; 288: 15035-15045.
19. Kim D, Nguyen MD, Dobbin MM, Fischer A, Sananbenesi F, Rodgers JT et al. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J 2007; 26: 3169-3179.
20. Lee JC, Shin JH, Park BW, Kim GS, Kim JC, Kang KS et al. Region-specific changes in the immunoreactivity of SIRT1 expression in the central nervous system of SOD1(G93A) transgenic mice as an in vivo model of amyotrophic lateral sclerosis. Brain Res 2012; 1433: 20-28.
21. Körner S, Böselt S, Thau N, Rath KJ, Dengler R, Petri S. Differential sirtuin expression patterns in amyotrophic lateral sclerosis (ALS) postmortem tissue: neuroprotective or neurotoxic properties of sirtuins in ALS? Neurodegener Dis 2013; 11: 141-152.
22. Song W, Song Y, Kincaid B, Bossy B, Bossy-Wetzel E. Mutant SOD1G93A triggers mitochondrial fragmentation in spinal cord motor neurons: neuroprotection by SIRT3 and PGC-1a. Neurobiol Dis 2013; 51: 72-81.
23. Donmez G, Outeiro TF. SIRT1 and SIRT2: emerging targets in neurodegeneration. EMBO Mol Med 2013; 5: 344-352.
24. Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 2000; 403: 795-800.
25. Vaquero A, Scher M, Lee D, Erdjument-Bromage H, Tempst P, Reinberg D. Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin. Mol Cell 2004; 16: 93-105.
26. Pucci B, Villanova L, Sansone L, Pellegrini L, Tafani M, Carpi A et al. Sirtuins: the molecular basis of beneficial effects of physical activity. Intern Emerg Med 2013; 8(Suppl 1): S23-S25.
27. Nakagawa T, Guarente L. Sirtuins at a glance. J Cell Sci 2011; 124(Pt 6): 833-838.
28. Zhang F, Wang S, Gan L, Vosler PS, Gao Y, Zigmond MJ et al. Protective effects and mechanisms of sirtuins in the nervous system. Prog Neurobiol 2011; 95: 373-395.
29. Song NY, Surh YJ. Janus-faced role of SIRT1 in tumorigenesis. Ann N Y Acad Sci 2012; 1271: 10-19.
30. Li X. SIRT1 and energy metabolism. Acta Biochim Biophys Sin (Shanghai) 2013; 45: 51-60.
31. Belden WJ, Dunlap JC. Aging well with a little wine and a good clock. Cell 2013; 153: 1421-1422.
32. Donmez G. The neurobiology of sirtuins and their role in neurodegeneration. Trends Pharmacol Sci 2012; 33: 494-501.
33. Yang Y, Duan W, Li Y, Yan J, Yi W, Liang Z et al. New role of silent information regulator 1 in cerebral ischemia. Neurobiol Aging 2013; 34: 2879-2888.
34. Pasinetti GM, Bilski AE, Zhao W. Sirtuins as therapeutic targets of caprylic triglyceride in ALS therapy. Cell Res 2013; 23: 1073-1074.
35. Crosio C, Valle C, Casciati A, Iaccarino C, Carrì MT. Astroglial inhibition of NF-kB does not ameliorate disease onset and progression in a mouse model for amyotrophic lateral sclerosis (ALS). PLoS One 2011; 6: e17187.
36. Ripps ME, Huntley GW, Hof PR, Morrison JH, Gordon JW. Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 1995; 92: 689-693.
37. Pesaresi MG, Amori I, Giorgi C, Ferri A, Fiorenzo P, Gabanella F et al. Mitochondrial redox signalling by p66Shc mediates ALS-like disease through Rac1 inactivation. Hum Mol Genet 2011; 20: 4196-4208.
38. Encinas M, Iglesias M, Liu Y, Wang H, Muhaisen A, Ceña V et al. Sequential treatment of SH-SY5Y cells with retinoic acid and brain-derived neurotrophic factor gives rise to fully differentiated, neurotrophic factor-dependent, human neuron-like cells. J Neurochem 2000; 75: 991-1003.
39. Song KS, Scherer PE, Tang Z, Okamoto T, Li S, Chafel M et al. Expression of caveolin-3 in skeletal, cardiac, and smooth muscle cells. Caveolin-3 is a component of the sarcolemma and co-fractionates with dystrophin and dystrophin-associated glycoproteins. J Biol Chem 1996; 271: 15160-15165.
40. Tang Z, Scherer PE, Okamoto T, Song K, Chu C, Kohtz DS et al. Molecular cloning of caveolin-3, a novel member of the caveolin gene family expressed predominantly in muscle. J Biol Chem 1996; 271: 2255-2261.